Wegovy (semaglutide) improved symptoms and physical function in patients with obesity,diabetes and a common type of heart failure
Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure. (heart failure with preserved ejection fraction)
The study, presented at the American College of Cardiology conference and published in the New England Journal of Medicine, reports results from the second large trial Novo has conducted on Wegovy in heart failure with preserved ejection fraction, or HFpEF. The first trial, which showed positive results last year, was in patients who had obesity and HFpEF, but not diabetes.
Novo said it submitted the results of these two trials to regulators earlier this year and is seeking approval for a new indication in HFpEF. Wegovy last month got FDA clearance for its first usage besides weight loss — preventing cardiovascular complications in people with heart disease.
Wegovy is part of a booming class of diabetes and obesity treatments called GLP-1 drugs that deliver substantial amounts of weight loss, but they are costly and have been slow to gain widespread insurance coverage. Getting additional indications beyond weight loss could boost drugmakers’ arguments that the drugs are worth their cost and help streamline coverage.
See- "Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes"- Authors: Mikhail N. Kosiborod, M.D., Mark C. Petrie, M.D., Barry A. Borlaug, M.D., Javed Butler, M.D., Melanie J. Davies, M.D., G. Kees Hovingh, M.D., Dalane W. Kitzman, M.D., +25, for the STEP-HFpEF DM Trial Committees and Investigators. Published April 6, 2024 DOI: 10.1056/NEJMoa2313917.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins